EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Antitumor effects of intracranial injection of B7-H3-targeted Car-T and Car-Nk cells in a patient-derived glioblastoma xenograft model

Tetsuro Tachi, Noriyuki Kijima, Hideki Kuroda, Syunya Ikeda, Koki Murakami, Tomoyoshi Nakagawa, Moto Yaga, Kanji Nakagawa, Reina Utsugi, Ryuichi Hirayama, Yoshiko Okita, Naoki Kagawa und 3 weitere

Cancer Immunology, Immunotherapy · 05.10.2024 · 73 (12)

DOI: 10.1007/s00262-024-03808-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 05.10.2024. Verfasst von Tetsuro Tachi und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka, 5650871, Japan. Hauptthemen laut MEDLINE: Glioblastoma, B7 Antigens, Killer Cells, Natural, Xenograft Model Antitumor Assays. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science (JSPS) KAKENHI, Japan Agency for Medical Research and Development (AMED), Japan Brain Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Glioblastoma multiforme (GBM) is the most lethal primary brain tumor for which novel therapies are needed. Recently, chimeric antigen receptor (CAR) T cell therapy has been shown to be effective against GBM, but it is a personalized medicine and requires high cost and long time for the cell production. CAR-transduced natural killer (NK) cells can be used for "off-the-shelf" cellular immunotherapy because they do not induce graft-versus-host disease. Therefore, we aimed to analyze the anti-GBM effect of CAR-T or NK cells targeting B7-H3, which is known to be highly expressed in GBM.

Methods

CAR-T cells targeting B7-H3 were generated using previously reported anti-B7-H3 scFv sequences. Cord blood (CB)-derived NK cells transduced with the B7-H3 CAR were also generated. Their anti-GBM effect was analyzed in vitro. The antitumor effect of intracranial injection of the B7-H3 CAR-T or NK cells was investigated in an in vivo xenograft model with patient-derived GBM cells.

Results

Both B7-H3 CAR-T cells and CAR-NK cells exhibited marked cytotoxicity against patient-derived GBM cells in vitro. Furthermore, intracranial injection of CAR-T cells and CAR-NK cells targeting B7-H3 resulted in a significant antitumor effect against patient-derived GBM xenografts.

Conclusion

Not only CAR-T cells but also CB-derived CAR-NK cells targeting B7-H3 may have the potential to eliminate GBM cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaB7 AntigensKiller Cells, NaturalXenograft Model Antitumor AssaysImmunotherapy, AdoptiveReceptors, Chimeric AntigenBrain NeoplasmsAnimalsHumansMiceCell Line, TumorFemale

Stichwörter der Autor:innen

Antitumor effectB7-H3CAR-NK cell therapyGlioblastoma (GBM)

Substanzen

B7 AntigensCD276 protein, humanReceptors, Chimeric Antigen

Autor:innen und Institutionen

  • Department of Neurosurgery, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka, 5650871, Japan.
  • Department of Neurosurgery, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka, 5650871, Japan. n-kijima@nsurg.med.osaka-u.ac.jp.
  • World Premier International Immunology Frontier Research Center, Osaka University, Suita, Osaka, Japan.
  • Department of Respiratory Medicine, Osaka General Hospital, Osaka, Japan.
  • Department of Pediatrics, Faculty of Medicine, University of Toyama, Toyama, Japan.
  • World Premier International Immunology Frontier Research Center, Osaka University, Suita, Osaka, Japan. hnaoki@bldon.med.osaka-u.ac.jp.

Förderung

  • Japan Society for the Promotion of Science (JSPS) KAKENHI
  • Japan Agency for Medical Research and Development (AMED)
  • Japan Brain Foundation
  • Osaka Community Foundation
  • Mochida Memorial Foundation for Medical and Pharmaceutical Research
  • Astellas Foundation for Medical Research on Metabolic Disorders
  • Takeda Science Foundation
  • Osaka University

Zitieren

APA

Tachi, T., Kijima, N., Kuroda, H., Ikeda, S., Murakami, K., Nakagawa, T., Yaga, M., Nakagawa, K., Utsugi, R., Hirayama, R., Okita, Y., Kagawa, N., Kishima, H., Imai, C., & Hosen, N. (2024). Antitumor effects of intracranial injection of B7-H3-targeted Car-T and Car-Nk cells in a patient-derived glioblastoma xenograft model. Cancer Immunology, Immunotherapy, 73(12). https://doi.org/10.1007/s00262-024-03808-0

Vancouver

Tachi T, Kijima N, Kuroda H, Ikeda S, Murakami K, Nakagawa T, et al. Antitumor effects of intracranial injection of B7-H3-targeted Car-T and Car-Nk cells in a patient-derived glioblastoma xenograft model. Cancer Immunology, Immunotherapy. 2024;73(12). doi:10.1007/s00262-024-03808-0

BibTeX
@article{Tachi2024,
  author = {Tachi, Tetsuro and Kijima, Noriyuki and Kuroda, Hideki and Ikeda, Syunya and Murakami, Koki and Nakagawa, Tomoyoshi and Yaga, Moto and Nakagawa, Kanji and Utsugi, Reina and Hirayama, Ryuichi and Okita, Yoshiko and Kagawa, Naoki and Kishima, Haruhiko and Imai, Chihaya and Hosen, Naoki},
  title = {Antitumor effects of intracranial injection of B7-H3-targeted Car-T and Car-Nk cells in a patient-derived glioblastoma xenograft model},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2024},
  volume = {73},
  number = {12},
  doi = {10.1007/s00262-024-03808-0}
}
Kostenlos starten →